Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Condition(s):SCLC, Extensive StageLast Updated:April 12, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):SCLC, Extensive StageLast Updated:April 12, 2022Recruiting
Condition(s):Skin NeoplasmsLast Updated:July 3, 2018Completed
Condition(s):Uterine NeoplasmsLast Updated:February 14, 2024Recruiting
Condition(s):Breast Neoplasm FemaleLast Updated:October 20, 2022Not yet recruiting
Condition(s):Solid Tumors, AdultLast Updated:June 13, 2023Not yet recruiting
Condition(s):Hematologic Neoplasms; Solid NeoplasmLast Updated:June 15, 2023Recruiting
Condition(s):Breast NeoplasmsLast Updated:November 2, 2022Recruiting
Condition(s):Colorectal Cancer; Pancreatic CancerLast Updated:February 7, 2024Not yet recruiting
Condition(s):Breast CancerLast Updated:April 27, 2022Not yet recruiting
Condition(s):Gynecologic CancerLast Updated:July 28, 2022Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.